Bio-Rad Laboratories, Inc.
BIO
Classificação em ações
#2165
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules,... Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Preço da ação
$355.52
Valor de mercado
$9.51B
Variação (1 dia)
0.98%
Variação (1 ano)
10.44%
País
US
Negociar Bio-Rad Laboratories, Inc. (BIO)
Categoria
Healthcare
Rácio P/E de Bio-Rad Laboratories, Inc. (BIO)
Rácio P/E em October 2026 TTM: 43.51
De acordo com os últimos relatórios financeiros e o preço das ações da Bio-Rad Laboratories, Inc., o rácio P/E atual (TTM) é 43.51. No final de 2023, a empresa tinha um P/E de -14.80.
Histórico do rácio P/E da Bio-Rad Laboratories, Inc. de 2000 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 43.51 | -964.99% |
| 2024 | -5.03 | -66.04% |
| 2023 | -14.80 | 328.61% |
| 2022 | -3.45 | -165.17% |
| 2021 | 5.30 | 16.45% |
| 2020 | 4.55 | -27.54% |
| 2019 | 6.28 | -67.28% |
| 2018 | 19.19 | -68.89% |
| 2017 | 61.69 | -67.67% |
| 2016 | 190.80 | 433.20% |
| 2015 | 35.78 | -8.68% |
| 2014 | 39.18 | -13.74% |
| 2013 | 45.42 | 158.67% |
| 2012 | 17.56 | 16.26% |
| 2011 | 15.11 | -2.48% |
| 2010 | 15.49 | -15.26% |
| 2009 | 18.28 | -19.87% |
| 2008 | 22.81 | -23.37% |
| 2007 | 29.77 | 41.23% |
| 2006 | 21.08 | 0.79% |
| 2005 | 20.91 | -3.29% |
| 2004 | 21.63 | 12.38% |
| 2003 | 19.24 | 34.25% |
| 2002 | 14.33 | -18.83% |
| 2001 | 17.66 | 41.42% |
| 2000 | 12.49 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 33.11 | -23.90% |
US
|
|
| 21.39 | -50.84% |
IE
|
|
| 28.94 | -33.47% |
US
|
|
| 17.34 | -60.15% |
US
|
|
| - | - |
DE
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.